AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

JAAD and beyond - best of the year from JEADV 2023

Description

This session summarizes notable articles from the 2023 Journal of the European Academy of Dermatology and Venereology (JEADV). Key findings include a study on advanced melanoma where anti-PD-1 and BRAF inhibitors showed promising survival rates and lymph node surgery findings. Research on basal cell carcinoma emphasized the significance of patients' overall health in treatment outcomes. Advances in imaging techniques enable better pre-surgical decisions for skin lesions. A global consensus for vitiligo management was introduced, along with new treatment options for melasma that replaced hydroquinone with thiamidol. In autoimmune dermatology, studies on rare diseases and the impact of biologics on psoriasis were highlighted. Eczema management updates showed costs associated with treatment and the emergence of new therapies, including emollients for atopic dermatitis prevention. Additionally, transcriptomic studies in acne and rosacea revealed important insights into barrier protein expression. The session also featured discussions on guideline updates and the journal's publishing metrics, showcasing the widespread impact of influential research.

View more

Conclusions

  • Adjuvant treatment with PD-1 antibodies and BRAF/MEK inhibitors in melanoma shows a 12-month resection-free survival rate of 78.9% and 86.5% respectively in a study involving 1194 patients.
  • Total lymph node ektomy is not superior to Sentinel lymph node ektomy in melanoma treatment.
  • In older patients with basal cell carcinoma, the Charleston Comorbidity Index suggests that those with fewer comorbidities have significantly better survival rates than those with many comorbidities.
  • A higher aCCI (Charlson Comorbidity Index) score is associated with a lower median survival in patients undergoing Mohs Micrographic Surgery for facial basal cell carcinoma.
  • Implementing imaging techniques like reflectance confocal microscopy improves diagnostic accuracy for skin lesions before surgical intervention.
  • Topical rapamycin is an effective treatment for facial angiofibromas associated with tuberous sclerosis, showing improvement in 90% of patients.
  • New international recommendations for vitiligo management emphasize shared decision-making and tailored treatment based on individual patient characteristics.
  • The New Trio for melasma treatment, combining thiamidol, retinoic acid, and glucocorticoid, shows better quality of life outcomes than Kligman's trio.
  • Updates to European guidelines for autoimmune conditions include new diagnostic methods and treatment options, emphasizing the significance of shared patient care.
  • Systematic reviews highlight the substantial societal costs related to atopic dermatitis, driven mainly by severe cases.
  • Regular use of emollients in infants significantly reduces the likelihood of developing atopic dermatitis.
  • There are identifiable alterations in barrier-related gene expressions in acne-involved skin, suggesting potential new therapeutic targets for treatment.
  • Schumann K, Mauch C, Klespe KC et al. PD-1 Ab and BRAF/MEK inhibitors in adjuvant melanoma treatment. JEADV 2023; 37:894-906.
  • Van Coile L, Brochez L, Verhaeghe E, Boone B, Meertens A, Ongenae K, Hoorens I. A critical re-evaluation of Mohs Micrographic Surgery (MMS) for facial basal cell carcinoma in older adults. JEADV 2023; 37:1792-1798.
  • Perino et al. Reflectance confocal microscopy (RCM): Concordance with horizontal sectioning histology. JEADV 2023; 38:124-135.
  • Balestri R, Rizzoli L, Pedrolli A et al. Topical mTOR inhibitor (rapamycin) therapy in facial angiofibromas in tuberous sclerosis. JEADV 2023; 37:474-487.
  • Van Geel N, Speckaert R, Taieb A et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force. JEADV 2023; 37: 2173-2184.
  • Antiga E, Bech R, Maglie R, Genovese G, Borradori L et al. European guidelines paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. JEADV 2023; 37:1118-1134.
  • Zouboulis C, Kaleta K, Broniatowska E, Jariene V, Nikolakis G. Clinical Data of children and adults with atrophic papulosis. JEADV 2023; 37:810-816.
  • Navarini AA, Prinz JC, Morita A, Tsai TF, Viguier et al. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study. JEADV 2023.
  • Augustin M, Misery L, von Kobyletzki L et al. Systematic literature review assessing the overall costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. JEADV 2022; 36:2316-2224.
  • Wollenberg et al. First update of the living European guideline on atopic eczema. JEADV 2023; 37:e1283-e1287.
  • Ahn J, Lee DJH, Na C et al. Facial erythema in patients with atopic dermatitis treated with Dupilumab. JEADV 2023; 37: 2140-2152.
  • Blauvelt A, Kircik L, Papp KA, Simpson E et al. Ruxolitinib cream against itch in atopic dermatitis. JEADV 2023; 37:136-147.
  • Liang J, Hu F, Tang H et al. Systematic review and network meta-analysis of different types of emollients for the prevention of atopic dermatitis in infants. JEADV 2023; 37:1-10.
  • Dull K, Lenart K, Dajnoki Z et al. Barrier function-related genes and proteins have altered expression in acne-involved skin. JEADV 2023; 37:1415-1424.